Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1029 of 6351
-
New drug combo shows promise against childhood brain tumors
Disease control OngoingIndoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism has been implicated in regulating immune responses in settings as diverse as infe…
Phase 2 • Sponsor: Theodore S. Johnson • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Immunotherapy before surgery shows promise for mesothelioma patients
Disease control OngoingThe proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard bi-/tri-modality therapy.
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could skipping axillary surgery be safe for early breast cancer patients?
Disease control OngoingThe VENUS trial is a prospective, multicenter, noninferiority, randomized, controlled clinical trial that compares sentinel lymph node biopsy versus no axillary surgery in women with early breast cancer (tumor \<5cm) and node-negative after clinical palpation and axillary ultraso…
Sponsor: University of Campinas, Brazil • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Can a nasal insulin spray rev up brain energy and sharpen thinking in psychosis?
Disease control CompletedThis clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and healthy controls.
Phase 2 • Sponsor: Mclean Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could an Immune-Suppressing drug treat some forms of schizophrenia?
Disease control Recruiting nowSome people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly…
Phase 1/2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a Tailor-Made felt dressing speed up diabetic wound healing?
Disease control Recruiting nowThe Surgical Outpatient Clinic at Molde Hospital has since 2015 offered specialized treatment for patients with diabetic foot ulcers. This treatment is given by an interdisciplinary diabetic foot ulcer team. The standard treatment for diabetic foot ulcers is relief, a method with…
Sponsor: Helse Møre og Romsdal HF • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Eye implant could replace monthly shots for diabetes-related vision loss
Disease control OngoingThis study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg) every 4 weeks (Q4W). The substudy will evaluate safet…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Brain bypass device aims to give hand control back to paralyzed patients
Disease control Recruiting nowThis is a single-cohort early feasibility trial to determine whether an investigational device called the Bidirectional Neural Bypass System can lead to the restoration of movement and sensation in the hand and wrist of up to seven individuals with tetraplegia.
Sponsor: Chad Bouton • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug shows promise for shrinking painful NF1 tumors
Disease control OngoingThis study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up …
Phase 2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for marginal zone lymphoma: Chemo-Free combo shows promise
Disease control OngoingSingle-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma (EMZL). It is planned to recruit 130 patients. Additional patients with Splenic Marginal Zone Lymphoma (SMZL), up to 30, and Nodal Marginal Zone Lymphoma (NMZL), up to 15, will be included in …
Phase 2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
A simple body scan may spot fatty liver disease without needles
Diagnosis Recruiting nowA generic screening study to establish structural and/or functional baselines of specific organs.
Sponsor: Richmond Research Institute • Aim: Diagnosis
Last updated Aug 21, 2026 00:00 UTC
-
Chemo-Free hope: new combo aims to outsmart CLL
Disease control CompletedThe aim of this study is to test the potential benefit of an innovative combination of targeted therapy over the standard the immunochemotherapy (FCR). The interest in this study resides in an MRD driven discontinuation of the novel agents, and a fixed maximum duration of these a…
Phase 2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug targets genetic dementia in small trial
Disease control CompletedA Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.
Phase 2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Can surgery boost control of spread prostate cancer?
Disease control OngoingMAZINGA is a prospective, single-group pilot study evaluating disease control after robot-assisted radical prostatectomy with extended pelvic lymph-node dissection in men with oligometastatic hormone-sensitive prostate adenocarcinoma who have received androgen-deprivation therapy…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for Tough-to-Treat myeloma: experimental drug shows promise
Disease control CompletedIn the phase 1 portion of the study, the primary objectives are to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma …
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail shows promise for Hard-to-Treat lung cancer
Disease control CompletedThe objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following t…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
A gel that may help the cervix heal from HPV lesions faces a test
Disease control CompletedPhase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV-HR. All the patients included in the study will be randomized …
Sponsor: Procare Health Iberia S.L. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo aims to shrink endometrial tumors
Disease control OngoingThis study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New combo attack shows promise against tough pancreatic tumors
Disease control OngoingThe purpose of this study is to evaluate the efficacy of modified FOLFIRINOX followed by stereotactic body radiotherapy (SBRT) in patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC). The primary hypothesis will be to determin…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo aims to boost survival in older AML patients
Disease control OngoingRandomized phase III, multicentre, open label clinical trial to compare pevonedistat in combination with azacytidine versus azacytidine alone, which can be considered a standard of care for patients with newly diagnosed acute myeloid leukemia not eligible for intensive chemothera…
Phase 3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC